Explore the Knowledge Graph

Drugs

Every drug, from preclinical program to approved product

Coverage

StageWhat you get
Approved Every drug approved by the FDA, EMA, or Health Canada: 4,800+ of them
Clinical-stage Every drug tested in a ClinicalTrials.gov trial since 2020, plus the experimental assets of every company with a clinical-stage program: 17,400+ investigational and 9,200+ experimental compounds
Preclinical Every preclinical program companies have disclosed in SEC filings, press releases, and pipeline pages: 39,700+ programs, half with no named asset yet, showing activity before a drug exists

Where it connects

Drug record Dolutegravir DB08930 drug · small molecule · approved, investigational
Targets What each drug binds, and whether it activates or blocks it
nameGag-Pol polyprotein gene_namepol uniprotkb_accessionQ7ZJM1 action_typeinhibitor pharmacological_actionyes organism_nameHuman immunodeficiency virus 1 cellular_locationnull +17 more relationships
Diseases Approved and investigational indications
titleHuman Immunodeficiency Virus Type 1 (HIV-1) Infection drugbank_idDBCOND0045921 meddra_idllt/10068341 snomed_idc/40780007 icd10_idc/B20 1 of 1 indicated condition
Clinical trials Every trial that tested it, with phase, status, and posted results
NCT00042289 NCT00555035 NCT00631592 NCT00708110 NCT00726336 NCT00774111 NCT00774735 NCT00796263 NCT00828763 NCT00858455 +297 more
NCT00631592.phases[1] NCT00631592.statuscompleted NCT00796263.phases[3] NCT00796263.statusrecruiting NCT00042289.phases[]
Companies The owner today, through every merger and acquisition
drugDolutegravir trialNCT00631592 sponsor.title (as filed)ViiV Healthcareindependent subsidiary parents[0].nameGlaxoSmithKline
Products Every brand, strength, and package it's sold under
product_name[0]ACRIPTEGA product_name[1]DILTRA product_name[2]DINISVIR 50 product_name[3]Dolutegravir +45 more

Zoom in

Approved GLP-1 receptor drugs, ranked by half-life
drugdrug_drugbank_idhalf-life as reportednormalized (h)
SemaglutideDB13928168 hours168
AlbiglutideDB090434–7 days96–168
TirzepatideDB151715 days120
DulaglutideDB090455 days120
DulaglutideDB090453.75 days89.9
LiraglutideDB0665513 hours13
LixisenatideDB092653 hours3
ExenatideDB012762.4 hours2.4
Dolutegravir indications, by kind
kindconditioncountrymax_phaseroutedose_formage_groups
used_in_combination_to_treatHIV-1 InfectionUS4OralTabletadult, pediatric
adjunct_therapy_in_treatment_ofHIV-1 InfectionUS4OralTablet, Tablet for suspensionadolescent, pediatric
adjunct_therapy_in_treatment_ofHIV-1 InfectionUS4OralTablet, Tablet for suspensionadult
used_in_combination_to_treatHIV-1 InfectionUS4OralTabletadult

+8 more indications

Preclinical programs in HIV-1 infection
program_drugbank_identityraw_phaseraw_statustargetscompanies
DBPRG00153911HCW11-006preclinicalnullIL7, IL15, IL21HCW Biologics; Akron Biotech
DBPRG00137411nullpreclinicalactivegp120California Institute of Technology; Bill & Melinda Gates Foundation; Absci; Caltech
DBPRG00143637ASN3013preclinicalactiveenvAbsci; California Institute of Technology; Bill & Melinda Gates Foundation
DBPRG00040886CRV431preclinicalactivecyclophilin, cyclophilinsHepion Pharmaceuticals

+6 more programs

Dolutegravir structure
fieldvalue
moldb_formulaC20H19F2N3O5
molecular_weight419.3788
moldb_smiles[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2
moldb_inchikeyRHWKPHLQXYSBKR-BMIGLBTASA-N
logp0.98
polar_surface_area99.18
rule_of_fivetrue
salts[0]Dolutegravir sodium · DBSALT000943 · CAS 1051375-19-9
Dolutegravir interactions, by severity
interacting_drugdrug_drugbank_idseverityevidenceaction
DofetilideDB00204majorlevel_1increase_serum_concentration
MetforminDB00331moderatelevel_1increase_serum_concentration
PravastatinDB00175moderatelevel_2decrease_dynamics
Valproic acidDB00313moderatelevel_2decrease_dynamics
EtanerceptDB00005minorlevel_2increase_specific_effects

+934 more interactions

Dolutegravir adverse effects, against comparator
effectcondition IDregionroutearmcomparatorpercent
InsomniaDBCOND0017531USOralexperimental—<1%
InsomniaDBCOND0017531USOralcomparatordolutegravir/lamivudine3%
Diarrhea and Loose StoolsDBCOND0126047USOralexperimental—2%
increased alanine aminotransferase (ALT)DBCOND0102242USOralexperimental—9%

+86 more adverse effects

Dolutegravir names and identifiers
fieldvalue
nameDolutegravir
synonymsDolutegravir, GSK1349572, GSK572, S-349572, S/GSK1349572
cas_number1051375-16-6
uniiDKO1W9H7M1
chembl_idCHEMBL1229211
rxnorm_id1433868
pubchem_cid54726191
atc[3].titleIntegrase inhibitors

Questions it answers

  • Which compounds hit my target with a longer half-life than the incumbent? Efficacy and safety benchmarking
  • What's in development against this mechanism that hasn't reached a trial yet? Landscape and whitespace analysis
  • How do safety profiles compare across a drug class? Efficacy and safety benchmarking

All figures pulled as of November 2026.

Get answers you can trust, every time.